Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Certoparin · 4 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| Certoparin | EXPERIMENTAL | - |
| Unfractionated Heparin | ACTIVE_COMPARATOR | - |
| 1 | EXPERIMENTAL | Certoparin |
| 2 | ACTIVE_COMPARATOR | Heparin |
| Name | Type | Description |
|---|---|---|
| Certoparin | DRUG | Certoparin |
| Unfractionated Heparin | DRUG | solution, 5000 IU of unfractionated heparin in 0.3 ml, 3 times daily |
| Heparin | DRUG | 7500 IU of unfractionated heparin administered twice daily during the treatment period of 10 ± 2 days |
Inclusion Criteria: * Patients requiring hemodialysis * Patients requiring anticoagulation therapy during hemodialysis * Written informed consent Exclusion Criteria: * Hypersensitivity to study medication * Genetic abnormality or disease of clotting system * Prior major surgery or bleeding * Othe...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| ICON Plc | ICLR | 1 | N/A | Undisclosed |
| Penumbra, Inc. | PEN | 1 | - | Undisclosed |
| Boston Scientific Corporation | BSX | 1 | - | Undisclosed |
| AngioDynamics, Inc. | ANGO | 2 | N/A | Undisclosed |
Certoparin is an investigational small molecule being studied for cardiovascular conditions including persistent nonvalvular atrial fibrillation, thromboembolism, renal dialysis, and renal insufficiency. It is a low-molecular-weight heparin evaluated for thromboprophylaxis in acutely ill medical patients and for use in renal patients undergoing hemodialysis.
Certoparin is being developed by Novartis AG, a multinational pharmaceutical company listed on the NYSE under the ticker NVS. The drug is currently in clinical development for cardiovascular indications.
Certoparin is in Phase 3 clinical development. It has completed Phase 3 trials for persistent nonvalvular atrial fibrillation, embolism, and renal dialysis, as well as a Phase 1 pharmacokinetic study in renal insufficiency. It remains investigational and is not approved.
Certoparin has completed several clinical trials. NCT00171769, the AFFECT trial, studied it in persistent nonvalvular atrial fibrillation. NCT00311753 evaluated it for thromboprophylaxis in acutely ill medical patients with embolism. NCT01179620 tested it in renal patients undergoing hemodialysis, and NCT01660295 examined its pharmacokinetics in renal insufficiency.
Certoparin is a low-molecular-weight heparin, as indicated in the title of one of its clinical trials. It is being studied for its efficacy and safety in preventing thromboembolism in various patient populations, including those with atrial fibrillation and renal impairment.